Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KMKID
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2024230301A1 ADC-13
|
|||||
| Synonyms |
WO2024230301A1 ADC-13
Click to Show/Hide
|
|||||
| Organization |
NOVACYTE THERAPEUTICS CO., LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.2
|
|||||
| Structure |
|
|||||
| Antibody Name |
trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.5 nM | Low B7H3 expression (B7H3+) | ||
| Method Description |
Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into
3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.6 nM | High B7H3 expression (B7H3 +++) | ||
| Method Description |
Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into
3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||